Last reviewed · How we verify
NCT05477849
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Phase 1 trial testing Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection in Advanced Malignant Solid Tumor in 30 participants. Currently enrolling.
31 October 2025
Quick facts
| Lead sponsor | Shanghai Virogin Biotech Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 August 2022 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection — full drug profile →
Conditions studied
- Advanced Malignant Solid Tumor — all drugs for Advanced Malignant Solid Tumor →
Sponsor
Shanghai Virogin Biotech Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Malignant Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E. · · 2023 · cited 13× · PMID 37455828 · DOI 10.37349/etat.2023.00146 -
miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.
Toropko M, Chuvpilo S, Karabelsky A. · · 2024 · cited 8× · PMID 39204331 · DOI 10.3390/pharmaceutics16080986 -
Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
Vázquez-Arreguín K, Rivera-Caraballo KA, Ventarapragada D, Chiocca EA, et al · · 2025 · cited 6× · PMID 40702727 · DOI 10.1016/j.ymthe.2025.07.034
Verify or expand the search:
- PubMed search for NCT05477849
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignant Solid Tumor
Currently open trials in the same condition.
- NCT07293754 — An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06718946 — Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT06592417 — To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT04165590 — Plasmodium Immunotherapy for Advanced Malignant Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05477849 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Virogin Biotech Co., Ltd.
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05477849.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing